Atherosclerotic disease and cardiovascular risk factors in postmenopausal breast cancer survivors: a case–control study

References

• American Cancer Society. Breast Cancer Facts & Figures 2016-2017. Atlanta: American Cancer Society, Inc. 2015
   Google Scholar
• Gironés R, Torregrosa D, Díaz-Beveridge R. Co morbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol 2010;73:236–45
   PubMed Web of Science ®Google Scholar
• Patterson RE, Flatt SW, Saquib N. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat 2010;122:859–65
   PubMed Web of Science ®Google Scholar
• Buttros D, Nahas EA, Vespoli HL, et al. Risk of metabolic syndrome in postmenopausal breast cancer survivors. Menopause 2013;20:448–54
   PubMed Web of Science ®Google Scholar
• Poloni PF, De Luca Vespoli H, Almeida-Filho BS, et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case–control study. Climacteric 2017;20:491–7
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858–69
   PubMed Web of Science ®Google Scholar
• Mosca L, Banka CL, Benjamin EJ. Expert Panel/Writing Group; American Heart Association; American Academy of Family Physicians; American College of Obstetricians and Gynecologists; American College of Cardiology Foundation; Society of Thoracic Surgeons; American Medical Women's Association; Centers for Disease Control and Prevention; Office of Research on Women's Health; Association of Black Cardiologists; American College of Physicians; World Heart Federation; National Heart, Lung, and Blood Institute; American College of Nurse Practitioners. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. Circulation 2007;115:1481–501
   PubMed Web of Science ®Google Scholar
• Bardia A, Arieas ET, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012;131:907–14
   PubMed Web of Science ®Google Scholar
• Long A, Long B, Koyfman A. Non-traditional risk factors for atherosclerotic disease: a review for emergency physicians. Am J Emerg Med 2017;36:494–97
   PubMed Web of Science ®Google Scholar
• Melichar B, Kalábová H, Ungermann L, et al. Intima-media thickness and laboratory parameters of atherosclerosis risk in patients with breast cancer. Anticancer Res 2012;32:4077–84
   PubMed Web of Science ®Google Scholar
• Whitlock MC, Yeboah J, Burke GL, et al. Cancer and its association with the development of coronary artery calcification: an assessment from the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc 2015;4:pii: e002533
   Web of Science ®Google Scholar
• Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer. JCO 2006;24:2779–85
   PubMed Web of Science ®Google Scholar
• Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer 2007;109:650–7
   PubMed Web of Science ®Google Scholar
• Gallicchio L, Calhoun C, Riseberg D, Helzlsouer K. Cardiovascular health among black and white breast cancer patients initiating aromatase inhibitor therapy. Breast J 2017;23:206–9
   PubMed Web of Science ®Google Scholar
• Lorenz MW, Markus HS, Bots ML, Riswall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic and meta-analysis. Circulation 2007;115:459–67
   PubMed Web of Science ®Google Scholar
• Nahas EA, Nahas-Neto J, Orsatti CL, et al. Evaluation of clinical and inflammatory markers of subclinical carotid atherosclerosis in postmenopausal women. Menopause 2014;21:982
   PubMed Web of Science ®Google Scholar
• Simon T, Boutouyrie P, Simon JM, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation 2002;106:2925–9
   PubMed Web of Science ®Google Scholar
• Stamatelopoulos KS, Lekakis JP, Poulakaki NA, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J 2004;147:1093–9
   PubMed Web of Science ®Google Scholar
• Nastri CA, Martins WP, Ferriani RA, Mauad Filho F, Reis FJC. Sonographic evaluation of endothelial function in letrozole and tamoxifen users. Maturitas 2008;61:340–4
   PubMed Web of Science ®Google Scholar
• Kalábová H, Melichar B, Ungermann L, et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011;28:1281–7
   PubMed Web of Science ®Google Scholar
• Seo DA, Cho Y, Lee S, et al. Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients. Korean J Intern Med 2017;25:1–10
   Google Scholar
• Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 2018;137:e30–66
   PubMed Web of Science ®Google Scholar
• Iliescu C, Grines CL, Herrmann J, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory. Cathet Cardiovasc Intervent 2016;87:895–9
   PubMedGoogle Scholar
• NCEP Expert Panel on the detection, evaluation, and treatment of high blood pressure in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Adult Treatment Panel III (ATP III). JAMA 2001;285:2444–9
   Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907–22
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Panel members. Strategies for subtypes– dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–47
   PubMed Web of Science ®Google Scholar
• Mercuri M, Tang R, Phillips RM, Bond MG. Ultrasound protocol and quality control procedures in the European Lacidipine Study Atherosclerosis. Blood Press Suppl 1996;4:20–3
   PubMedGoogle Scholar
• Smith SC, Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 2000;101:111–16
   PubMedGoogle Scholar
• Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol 2015;65:1065–74
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017;135:e146–603
   PubMed Web of Science ®Google Scholar
• Schneider JG, Tompkins C, Blumenthal RS, Mora S. The metabolic syndrome in women. Cardiol Rev 2006;14:286–91
   PubMedGoogle Scholar
• Healy LA, Ryan AM, Carroll P, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol 2010;22:281–8
   PubMed Web of Science ®Google Scholar
• Thomson CA, Thompson PA, Wright-Bea J, et al. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Women Health 2009;18:2041–7
   PubMed Web of Science ®Google Scholar
• Porto LA, Lora KJ, Soares JC, Costa LO. Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet 2011;284:1271–6
   PubMed Web of Science ®Google Scholar
• Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103–11
   PubMed Web of Science ®Google Scholar
• Zhao X, Ren G. Diabetes mellitus and prognosis in women with breast cancer. A systematic review and meta-analysis. Medicine 2016;95:e5602
   PubMed Web of Science ®Google Scholar
• Lega IC, Austin PC, Fischer HD, et al. The impact of diabetes on breast cancer treatments and outcomes: a population based study. Diabetes Care 2018;41:755–61
   PubMed Web of Science ®Google Scholar
• Eagle KA, Ginsburg GS, Musunuru K, et al. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation 2010;121:1447–54
   PubMed Web of Science ®Google Scholar
• Terranova CO, Lawler SP, Spathonis K, Eakin EG, Reeves MM. Breast cancer survivors' experience of making weight, dietary and physical activity changes during participation in a weight loss intervention. Support Care Cancer 2017;25:1455–63
   PubMed Web of Science ®Google Scholar
• Katzke VA, Kaaks R, Kuhn T. Lifestyle and cancer risk. Cancer J 2015;21:104–10
   PubMed Web of Science ®Google Scholar